The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting growing challenges in the biotech sector, Alnylam Pharmaceuticals lowered its 2026 sales outlook, triggering a significant drop in its stock price. This revision stems from slower growth in the transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) market, despite the company reporting second-quarter earnings that beat analyst expectations. The company attributed the guidance cut to the normalization of demand for its drug Amvuttra in second-line treatments after initial pent-up demand was satisfied.
Per market data, the company's stock (0HD2.L) faced intense selling pressure following the update, as concerns over long-term guidance outweighed the short-term earnings beat. According to reports, the downward revision reflects a transition in the market landscape where sales volumes are stabilizing following the initial launch phase of new therapies. This shift has dampened investor sentiment regarding the specialized rare-disease treatment market the company operates in.
Alnylam (0HD2.L) stood at $285.82 at the close of July 28, 2026, with the session seeing a range between $282 and $289.86. Traders are now monitoring the company's ability to regain growth momentum in light of the stated operational challenges. Looking at the economic calendar, there are no major upcoming catalysts specifically for the company in the next seven days, leaving the focus on how the market digests the revised long-term financial outlook.